LIPOSOMAL DOXORUBICIN WITH/WITHOUT BLEOMYCIN & VINCRISTINE FOR AIDS

这是一项开放标签、多中心、比较研究，旨在确定 脂质体多柔比星单用或联合应用的长期安全性和有效性 与硫酸长春新碱和硫酸博来霉素联合治疗 治疗晚期艾滋病相关KS。 受试者将入组， 随机接受脂质体阿霉素单独或与 硫酸长春新碱和硫酸博来霉素。 他们将被分层， 根据他们目前是否正在接受 GM-CSF和ACTG肿瘤委员会预后变量的G-CSF。 KS病变的状态将在第一次检查前进行评价。 研究药物给药，每隔一次给药前即刻 治疗周期，以及最后一次治疗结束后四周 治疗周期 受试者将接受最多25天的研究治疗 周期或累积剂量为500 mg/m2。

This is an open-label, multicenter, comparison study to determine the long-term safety and efficacy of liposomal dozorubicin alone or in combination with vincristine sulfate and bleomycin sulfate in the treatment of advanced AIDS-associated KS. Subjects will be enrolled and randomized to receive liposomal doxorubicin alone or in combination with vincristine sulfate and bleomycin sulfate. They will be stratified at randomization based on whether they are or are not currently receiving G-CSF of GM-CSF and by ACTG Oncology Committee prognostic variables. The status of KS lesions will be evaluated prior to the first administration of study medication, Immediately prior to every other cycle of treatment, and four weeks following the end of the last treatment cycle. Subjects will receive study treatment for up to 25 cycles or to a cumulative dose of 500mg/m2.